ReCor's updated renal denervation system OK’d in Europe

ReCor Medical's updated PARADISE (Percutaneous Renal Denervation) system has received CE Mark in Europe for treating resistant high blood pressure.

The 6 Fr over-the-wire ultrasound renal denervation device is designed to offer ultrasound therapy to reduce high blood pressure in treatment-resistant hypertension patients. The treatment parameters of Gen 2 have been enhanced to reduce energy delivery to 30 seconds by maximizing cooling of the endothelium and treating the nerves circumferentially.

The Gen 1 PARADISE system previously received CE Mark one year ago. It is the only CE-Marked system for renal denervation that is based on ultrasound, not radiofrequency energy, according to Menlo Park, Calif.-based ReCor, which developed the ultrasound system.

PARADISE is not currently available for clinical evaluation or sale in the U.S.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup